EUVIMEDEUVIMED entdecken
Crossref

Potential of Salicis cortex as a treatment option for inflammatory bowel disease

P Peterburs, C Büttner, E Lamy, I Mewis, M Soeberdt, C Abels

Planta Medica · 01.03.2026 · 92 (03) · 396

DOI: 10.1055/s-0045-1815396 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Planta Medica, erschienen am 01.03.2026. Verfasst von P Peterburs und 5 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Salicylic acid derivate 5-ASA is still a standard for maintenance therapy of Ulcerative Colitis (UC) but often with limited efficacy and adverse effects when used chronically. Therefore, extracts from Salicis spp. containing derivates of salicylic acid may be a safe and effective alternative. Extracts of Salix spp., are indicated for reducing lower back pain or minor articular pain due to their anti-inflammatory properties according to EMA monograph [ 1 ]. Thus, the potential of a Salix purpurea extract for the treatment of UC was investigated in vitro and in vivo . Anti-inflammatory effects were analysed using PBMCs from patients suffering from UC or Crohn’s disease, as well as from healthy donors. After stimulation with LPS, secretion of PGE2 or various cytokines was measured. A DSS-induced colitis model in mice was used to assess anti-inflammatory effects in vivo . To explore the potential role of the gut microbiome, effects on the microbiome were studied in a specific anaerobic fermentation system using Next-Generation-Sequencing. The extract reduced the secretion of some inflammatory markers from PBMCs of healthy and diseased donors in a concentration-dependent manner. In addition, a dose-dependent amelioration of DSS-induced inflammation was observed in mice. Moreover, microbiome analysis revealed the growth of health-related organisms (e.g. Catenibacterium or Blautia ), was promoted, while alpha diversity indices remained unchanged. The investigated Salix extract showed anti-inflammatory effects in vitro and in vivo and modulating effects on the gut microbiome, exhibiting potential as maintenance treatment after induction of remission by immunosuppressives and/or biologics following confirmation of efficacy in clinical trials. Publication History Article published online: 05 March 2026 © 2026. Thieme. All rights reserved. Georg Thieme Verlag KG Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany

Zitieren

APA

Peterburs, P., Büttner, C., Lamy, E., Mewis, I., Soeberdt, M., & Abels, C. (2026). Potential of Salicis cortex as a treatment option for inflammatory bowel disease. Planta Medica, 92(03), 396. https://doi.org/10.1055/s-0045-1815396

Vancouver

Peterburs P, Büttner C, Lamy E, Mewis I, Soeberdt M, Abels C. Potential of Salicis cortex as a treatment option for inflammatory bowel disease. Planta Medica. 2026;92(03):396. doi:10.1055/s-0045-1815396

BibTeX
@article{Peterburs2026,
  author = {Peterburs, P and Büttner, C and Lamy, E and Mewis, I and Soeberdt, M and Abels, C},
  title = {Potential of Salicis cortex as a treatment option for inflammatory bowel disease},
  journal = {Planta Medica},
  year = {2026},
  volume = {92},
  number = {03},
  pages = {396},
  doi = {10.1055/s-0045-1815396}
}
Kostenlos starten →